Core Viewpoint - Fujian Wancheng Biotechnology Group Co., Ltd. is planning to acquire a 49% stake in Nanjing Wanyou Commercial Management Co., Ltd. through cash payment, which constitutes a major asset restructuring and related party transaction according to relevant regulations [1][2]. Group 1 - The independent financial advisor, Huaxing Securities Co., Ltd., confirmed that there were no direct or indirect paid engagements of third parties in this transaction [1]. - The company has engaged China Merchants Securities Co., Ltd. as a financial advisor to provide relevant services for the transaction [2]. - The independent financial advisor concluded that the hiring of the mentioned third-party institutions is legal and compliant with the regulations set forth by the China Securities Regulatory Commission [2].
万辰集团: 华兴证券有限公司关于福建万辰生物科技集团股份有限公司本次交易符合《关于加强证券公司在投资银行类业务中聘请第三方等廉洁从业风险防控的意见》相关规定的核查意见